First published · Last updated
Long-acting IL-7 (NT-I7, efineptakin alfa) After CD19 CAR T-cell Therapy for Large B-cell Lymphoma: A Phase Ib Trial
Journal article reporting a Phase Ib trial of long-acting IL-7 (NT-I7, efineptakin alfa) after CD19 CAR T‑cell therapy for large B‑cell lymphoma. Publisher listed as Elsevier BV; publication date 2026-09-01.
Categories: public-health, science-and-space
Generated scores
Scores are based on the cited reporting and use a 1–10 scale. Read the methodology.
- Confidence
- 5/10
- Geographic reach
- 1/10
- Global importance
- 2/10
- Impact magnitude
- 2/10
- Positivity
- 5/10
- Urgency
- 1/10
Why it matters
Presents early-phase clinical trial data relevant to post–CAR T‑cell therapy treatment in large B‑cell lymphoma.

